Targeted Next-Generation Sequencing Indicates a Frequent Oligogenic Involvement in Primary Ovarian Insufficiency Onset.

next-generation sequencing oligogenic disease primary amenorrhea primary ovarian insufficiency secondary amenorrhea

Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2021
Historique:
received: 05 02 2021
accepted: 22 09 2021
entrez: 22 11 2021
pubmed: 23 11 2021
medline: 15 1 2022
Statut: epublish

Résumé

Primary ovarian insufficiency (POI) is one of the major causes of female infertility associated with the premature loss of ovarian function in about 3.7% of women before the age of 40. This disorder is highly heterogeneous and can manifest with a wide range of clinical phenotypes, ranging from ovarian dysgenesis and primary amenorrhea to post-pubertal secondary amenorrhea, with elevated serum gonadotropins and hypoestrogenism. The ovarian defect still remains idiopathic in some cases; however, a strong genetic component has been demonstrated by the next-generation sequencing (NGS) approach of familiar and sporadic POI cases. As recent evidence suggested an oligogenic architecture for POI, we developed a target NGS panel with 295 genes including known candidates and novel genetic determinants potentially involved in POI pathogenesis. Sixty-four patients with early onset POI (range: 10-25 years) of our cohort have been screened with 90% of target coverage at 50×. Here, we report 48 analyzed patients with at least one genetic variant (75%) in the selected candidate genes. In particular, we found the following: 11/64 patients (17%) with two variants, 9/64 (14%) with three variants, 9/64 (14%) with four variants, 3/64 (5%) with five variants, and 2/64 (3%) with six variants. The most severe phenotypes were associated with either the major number of variations or a worse prediction in pathogenicity of variants. Bioinformatic gene ontology analysis identified the following major pathways likely affected by gene variants: 1) cell cycle, meiosis, and DNA repair; 2) extracellular matrix remodeling; 3) reproduction; 4) cell metabolism; 5) cell proliferation; 6) calcium homeostasis; 7) NOTCH signaling; 8) signal transduction; 9) WNT signaling; 10) cell death; and 11) ubiquitin modifications. Consistently, the identified pathways have been described in other studies dissecting the mechanisms of folliculogenesis in animal models of altered fertility. In conclusion, our results contribute to define POI as an oligogenic disease and suggest novel candidates to be investigated in patients with POI.

Identifiants

pubmed: 34803902
doi: 10.3389/fendo.2021.664645
pmc: PMC8600266
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

664645

Informations de copyright

Copyright © 2021 Rossetti, Moleri, Guizzardi, Gentilini, Libera, Marozzi, Moretti, Brancati, Bonomi and Persani.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Mol Hum Reprod. 2016 Sep;22(9):669-78
pubmed: 27430550
Cell. 1995 Sep 22;82(6):959-68
pubmed: 7553856
PLoS One. 2010 Nov 03;5(11):e13823
pubmed: 21072205
Reprod Biomed Online. 2018 Feb;36(2):206-209
pubmed: 29169851
PLoS One. 2017 Apr 7;12(4):e0174264
pubmed: 28388629
Bioinformatics. 2019 Jun 1;35(11):1978-1980
pubmed: 30376034
Fertil Steril. 2017 Oct;108(4):694-702
pubmed: 28863940
Reproduction. 2017 Jun;153(6):R187-R204
pubmed: 28283672
Hum Reprod Update. 2018 Mar 1;24(2):119-134
pubmed: 29377997
Mol Hum Reprod. 1998 Aug;4(8):797-801
pubmed: 9733438
Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9905-9
pubmed: 7568242
Semin Reprod Med. 2006 Sep;24(4):262-9
pubmed: 16944423
Development. 1995 Aug;121(8):2645-54
pubmed: 7545575
Best Pract Res Clin Obstet Gynaecol. 2018 Apr;48:90-102
pubmed: 29503125
Trends Endocrinol Metab. 2018 Jun;29(6):400-419
pubmed: 29706485
Lab Invest. 2021 Mar;101(3):304-317
pubmed: 33303971
Development. 2007 Jul;134(14):2593-603
pubmed: 17553902
Genet Med. 2018 Dec;20(12):1528-1537
pubmed: 29790871
J Clin Endocrinol Metab. 2016 Dec;101(12):4541-4550
pubmed: 27603904
Clin Genet. 2018 Feb;93(2):408-411
pubmed: 29044499
Biomolecules. 2019 Nov 24;9(12):
pubmed: 31771306
J Clin Endocrinol Metab. 2015 Mar;100(3):994-1001
pubmed: 25514101
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
Nat Protoc. 2015 Oct;10(10):1556-66
pubmed: 26379229
J Ovarian Res. 2020 Nov 21;13(1):136
pubmed: 33220708
Front Genet. 2020 Nov 04;11:591672
pubmed: 33329737
Nat Rev Genet. 2013 Nov;14(11):794-806
pubmed: 24136506
Nat Med. 2011 Jun;17(6):684-91
pubmed: 21602802
Maturitas. 2020 Nov;141:9-19
pubmed: 33036707
Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11452-7
pubmed: 21693646
PLoS One. 2020 Oct 23;15(10):e0240795
pubmed: 33095795
Hum Reprod. 2017 Jul 1;32(7):1512-1520
pubmed: 28505269
Methods. 2010 Aug;51(4):364-73
pubmed: 20558295
Hum Reprod. 2017 Jan;32(1):248-255
pubmed: 27836978
Mol Endocrinol. 2001 Jun;15(6):946-59
pubmed: 11376113
Endocrinology. 2014 Sep;155(9):3624-37
pubmed: 24877628
Biomed J. 2020 Apr;43(2):115-123
pubmed: 32381463
Curr Vasc Pharmacol. 2019;17(6):604-609
pubmed: 30819073
Climacteric. 2019 Aug;22(4):403-411
pubmed: 30829083
Front Endocrinol (Lausanne). 2020 Sep 25;11:540683
pubmed: 33101191
Fertil Steril. 2011 Aug;96(2):e125-30
pubmed: 21683950
Int J Biol Sci. 2019 Jan 29;15(4):726-737
pubmed: 30906205
N Engl J Med. 2014 Mar 6;370(10):943-949
pubmed: 24597867
Clin Genet. 2020 May;97(5):779-784
pubmed: 32067224
Hum Reprod. 2016 Apr;31(4):905-14
pubmed: 26911863
Clin Genet. 2013 Mar;83(3):201-11
pubmed: 23131014
Am J Hum Genet. 2013 Apr 4;92(4):614-20
pubmed: 23541342
Hum Mutat. 2003 Dec;22(6):498-9
pubmed: 14635118
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Cell. 2020 Feb 6;180(3):585-600.e19
pubmed: 32004457
Nat Commun. 2018 Feb 15;9(1):688
pubmed: 29449677
Nucleic Acids Res. 2020 Jan 8;48(D1):D498-D503
pubmed: 31691815
J Clin Endocrinol Metab. 2014 Oct;99(10):E2129-32
pubmed: 25062452
Dev Biol. 2016 Oct 1;418(1):204-215
pubmed: 27506116
Life Sci. 2021 Jan 1;264:118654
pubmed: 33141043
Biol Proced Online. 2019 Oct 15;21:20
pubmed: 31636514
Endocrine. 2017 Dec;58(3):442-447
pubmed: 29067606
Hum Mol Genet. 2016 Dec 1;25(23):5223-5233
pubmed: 27798098
Fertil Steril. 2014 Jan;101(1):95-104.e3
pubmed: 24268707
Science. 2002 May 10;296(5570):1115-8
pubmed: 12004129
Fertil Steril. 2015 Jul;104(1):154-62.e2
pubmed: 25989972
Chromosoma. 2019 Sep;128(3):489-500
pubmed: 31489491
J Ovarian Res. 2018 Jun 18;11(1):48
pubmed: 29914564
Front Genet. 2019 Nov 14;10:1016
pubmed: 31803224
Hum Mol Genet. 2014 Jun 15;23(12):3327-42
pubmed: 24493794
J Clin Endocrinol Metab. 2006 Nov;91(11):4713-6
pubmed: 16954162
Gynecol Endocrinol. 2019 Dec;35(12):1037-1039
pubmed: 31274036
Hum Mutat. 2009 May;30(5):804-10
pubmed: 19263482
Fertil Steril. 2020 Jul;114(1):133-143
pubmed: 32553473
Cell Death Dis. 2019 Mar 13;10(3):245
pubmed: 30867408
Clin Genet. 2016 May;89(5):603-7
pubmed: 26771056
Hum Reprod. 2019 Mar 1;34(3):574-583
pubmed: 30689869
Hum Mutat. 2019 Jan;40(1):25-30
pubmed: 30304577
Sci Rep. 2016 Oct 13;6:35370
pubmed: 27734943
Endocrinology. 2019 Oct 1;160(10):2353-2366
pubmed: 31393557

Auteurs

Raffaella Rossetti (R)

Department of Endocrine and Metabolic Diseases and Lab of Endocrine and Metabolic Research, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Auxologico Italiano, Milan, Italy.

Silvia Moleri (S)

Department of Endocrine and Metabolic Diseases and Lab of Endocrine and Metabolic Research, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Auxologico Italiano, Milan, Italy.

Fabiana Guizzardi (F)

Department of Endocrine and Metabolic Diseases and Lab of Endocrine and Metabolic Research, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Auxologico Italiano, Milan, Italy.
Molecular Biology Laboratory, IRCCS Istituto Auxologico Italiano, Milan, Italy.

Davide Gentilini (D)

Bioinformatics and Statistical Genomics Unit, IRCCS Istituto Auxologico Italiano, Milan, Italy.

Laura Libera (L)

Department of Endocrine and Metabolic Diseases and Lab of Endocrine and Metabolic Research, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Auxologico Italiano, Milan, Italy.

Anna Marozzi (A)

Department of Medical Biotechnologies and Translational Medicine, University of Milan, Milan, Italy.

Costanzo Moretti (C)

Department of Systems Medicine, Tor Vergata University, Rome, Italy.

Francesco Brancati (F)

Medical Genetics, Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
Human Functional Genomics, IRCCS San Raffaele Pisana, Rome, Italy.

Marco Bonomi (M)

Department of Endocrine and Metabolic Diseases and Lab of Endocrine and Metabolic Research, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Auxologico Italiano, Milan, Italy.
Department of Medical Biotechnologies and Translational Medicine, University of Milan, Milan, Italy.

Luca Persani (L)

Department of Endocrine and Metabolic Diseases and Lab of Endocrine and Metabolic Research, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Auxologico Italiano, Milan, Italy.
Department of Medical Biotechnologies and Translational Medicine, University of Milan, Milan, Italy.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH